Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real-world Outcomes from a Prospective, Multicenter Deep Brain Stimulation Registry of Essential Tremor Patients
Movement Disorders
P3 - Poster Session 3 (5:30 PM-6:30 PM)
3-004

Large, multicenter patient outcome registries are an important source from which to collect real-world evidence (RWE). Ventral intermediate nucleus (Vim) Deep Brain Stimulation (DBS) is an increasingly recommended therapeutic approach in properly selected candidates to manage Essential Tremor (ET). This clinical evaluation will help provide RWE in patients implanted with a DBS system for ET.  

Here, we evaluate on-going registry outcomes derived from patients implanted with directional Deep Brain Stimulation systems with Multiple Independent Current Control (MICC) technology for treatment of Essential Tremor. 

In this prospective, on-label, multi-center, international DBS registry, enrolled patients are implanted with a directional MICC-based DBS system (Vercise, Boston Scientific). Patients are followed up to 3-years where ET symptoms and overall improvement in quality of life are evaluated. Clinical endpoint evaluated at baseline and during study follow-up timepoints include Fahn-Tolosa-Marin Rating Scale (FTMTRS), the Essential Tremor Rating Assessment Scale (TETRAS), Quality of Life in Essential Tremor Questionnaire (QUEST), and Global Impression of change. Adverse events are also being collected. 

Results from this ongoing, prospective, multicenter, international outcomes study demonstrate significant improvement in ET related symptoms and quality of life up to 12-month follow-up. A total of 50 subjects (27 males, mean age= 65.3 years, mean disease duration = 19.5 years) received DBS. At the 12-month follow-up, a mean 8.9-hours reduction in tremor was noted (self-reported, QUESD in a typical day. Additionally, regarding tremor severity, no subject reported marked disability while 82.6% reported mild disability (FTMTRS), and subjects saw a 63.7% mean-improvement in activities of daily living (TETRAS) at 12-months compared to baseline. No lead breakages/fractures were reported. 

Results from this ongoing, prospective, multicenter, international real-world outcomes study using multiple-source constant-current Directional DBS Systems for the treatment of Essential Tremor continue to demonstrate positive outcomes out to 12-months follow-up. 

Authors/Disclosures
Guenther Deuschl, MD, FAAN (Dept. of Neurology, Christain-Albrechts Univ)
PRESENTER
Dr. Deuschl has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Boston Scientific. Dr. Deuschl has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific Cavion Functional Neuromodulation. The institution of Dr. Deuschl has received research support from Medtronic. Dr. Deuschl has received publishing royalties from a publication relating to health care.
Norbert Kovacs No disclosure on file
Griet Loret, MD (UZ Gent, Dienst Neurologie) Dr. Loret has nothing to disclose.
Michael Barbe No disclosure on file
Jung Il-Lee (Samsung Medical Center, Sungkyunkwan University School of Medicine) No disclosure on file
Frederi C Clement No disclosure on file
Marta Blazquez Estrada Marta Blazquez Estrada has nothing to disclose.
Serge Jaumà Classen (Bellvitge University Hospital) No disclosure on file
David Pedrosa (University Hospital Giessen and Marburg) No disclosure on file
Jens Volkmann (Universitäts­klinikum Würzburg) No disclosure on file
Ana Oliveira (CHU de São João, Porto University) No disclosure on file
Steffen Paschen No disclosure on file
P.R. Schuurman No disclosure on file
Lilly Chen (Boston Scientific) No disclosure on file
Edward Goldberg (Boston Scientific) No disclosure on file